295
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Solute Carrier Family 7 Member 11 (SLC7A11) is a Potential Prognostic Biomarker in Uterine Corpus Endometrial Carcinoma

, &
Pages 481-497 | Received 19 Nov 2022, Accepted 18 Jan 2023, Published online: 05 Feb 2023

References

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
  • Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412–1428. doi:10.1016/s0140-6736(22)00323-3
  • Karpel HC, Chern JY, Smith JM, Smith AJ, Pothuri B. Utility of germline multi-gene panel testing in patients with endometrial cancer. Gynecol Oncol. 2022;165(3):546–551. doi:10.1016/j.ygyno.2022.04.003
  • Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016;34(35):4225–4230. doi:10.1200/jco.2016.69.4638
  • Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16–41. doi:10.1093/annonc/mdv484
  • Heudel P, Frenel JS, Dalban C, et al. Safety and efficacy of the mTOR inhibitor, vistusertib, combined with anastrozole in patients with hormone receptor-positive recurrent or metastatic endometrial cancer: the Victoria multicenter, open-label, phase 1/2 randomized clinical trial. JAMA Oncol. 2022;8(7):1001. doi:10.1001/jamaoncol.2022.1047
  • Horeweg N, Workel HH, Loiero D, et al. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nat Commun. 2022;13(1):1373. doi:10.1038/s41467-022-29040-x
  • Siegenthaler F, Lindemann K, Epstein E, et al. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification. Gynecol Oncol. 2022;165(2):230–238. doi:10.1016/j.ygyno.2022.02.024
  • Egawa-Takata T, Ueda Y, Ito K, et al. Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: a randomized Phase II study for advanced endometrial carcinoma. Cancer Sci. 2022;113(5):1693–1701. doi:10.1111/cas.15310
  • Liu D, Kaufmann GF, Breitmeyer JB, Dickson KA, Marsh DJ, Ford CE. The anti-ROR1 monoclonal antibody zilovertamab inhibits the proliferation of ovarian and endometrial cancer cells. Pharmaceutics. 2022;14(4):Apr. doi:10.3390/pharmaceutics14040837
  • Lheureux S, Matei DE, Konstantinopoulos PA, et al. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. J Immunother Cancer. 2022;10(3):e004233. doi:10.1136/jitc-2021-004233
  • Zheng J, Conrad M. The metabolic underpinnings of ferroptosis. Cell Metab. 2020;32(6):920–937. doi:10.1016/j.cmet.2020.10.011
  • Li J, Cao F, Yin HL, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11(2):88. doi:10.1038/s41419-020-2298-2
  • Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107–125. doi:10.1038/s41422-020-00441-1
  • Liang C, Zhang X, Yang M, Dong X. Recent progress in ferroptosis inducers for cancer therapy. Adv Mater. 2019;31(51):e1904197. doi:10.1002/adma.201904197
  • He J, Ding H, Li H, Pan Z, Chen Q. Intra-tumoral expression of SLC7A11 is associated with immune microenvironment, drug resistance, and prognosis in cancers: a pan-cancer analysis. Front Genet. 2021;12:770857. doi:10.3389/fgene.2021.770857
  • Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599–620. doi:10.1007/s13238-020-00789-5
  • Cheng X, Wang Y, Liu L, Lv C, Liu C, Xu J. SLC7A11, a potential therapeutic target through induced ferroptosis in colon adenocarcinoma. Front Mol Biosci. 2022;9:889688. doi:10.3389/fmolb.2022.889688
  • Guan Z, Chen J, Li X, Dong N. Tanshinone IIA induces ferroptosis in gastric cancer cells through p53-mediated SLC7A11 down-regulation. Biosci Rep. 2020;40(8):BSR20201807. doi:10.1042/bsr20201807
  • Huang W, Chen K, Lu Y, et al. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma. Neoplasia. 2021;23(12):1227–1239. doi:10.1016/j.neo.2021.11.002
  • Zhang N, Huang J, Xu M, Wang Y. LncRNA T-UCR Uc.339/miR-339/SLC7A11 axis regulates the metastasis of ferroptosis-induced lung adenocarcinoma. J Cancer. 2022;13(6):1945–1957. doi:10.7150/jca.65017
  • Safran M, Dalah I, Alexander J, et al. GeneCards Version 3: the human gene integrator. Database. 2010;2010:baq020. doi:10.1093/database/baq020
  • Consortium U. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 2021;49(D1):D480–d489. doi:10.1093/nar/gkaa1100
  • Liu W, Xie Y, Ma J, et al. IBS: an illustrator for the presentation and visualization of biological sequences. Bioinformatics. 2015;31(20):3359–3361. doi:10.1093/bioinformatics/btv362
  • Navarro Gonzalez J, Zweig AS, Speir ML, et al. The UCSC Genome Browser database: 2021 update. Nucleic Acids Res. 2021;49(D1):D1046–d1057. doi:10.1093/nar/gkaa1070
  • Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci. 2018;27(1):233–244. doi:10.1002/pro.3307
  • Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–w514. doi:10.1093/nar/gkaa407
  • Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–w560. doi:10.1093/nar/gkz430
  • Day RS, McDade KK. A decision theory paradigm for evaluating identifier mapping and filtering methods using data integration. BMC Bioinform. 2013;14:223. doi:10.1186/1471-2105-14-223
  • Lánczky A, Győrffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res. 2021;23(7):e27633. doi:10.2196/27633
  • Koch A, De Meyer T, Jeschke J, Van Criekinge W. MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data. BMC Genomics. 2015;16(1):636. doi:10.1186/s12864-015-1847-z
  • Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2018;10(3):277–288. doi:10.2217/epi-2017-0118
  • Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202. doi:10.1093/bioinformatics/btz210
  • Huang J, Chen Z, Ding C, Lin S, Wan D, Ren K. Prognostic biomarkers and immunotherapeutic targets among CXC chemokines in pancreatic adenocarcinoma. Front Oncol. 2021;11:711402. doi:10.3389/fonc.2021.711402
  • Cramer DW. The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin North Am. 2012;26(1):1–12. doi:10.1016/j.hoc.2011.10.009
  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
  • Brooks RA, Fleming GF, Lastra RR, et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;69(4):258–279. doi:10.3322/caac.21561
  • Li P, Brown S, Williams M, et al. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms. Blood. 2022. doi:10.1182/blood.2021015135
  • Lin X, Xiao M, Chen Z, Ding C, Zhang T, Li Q. Pancancer analyses reveal genomics and clinical characteristics of the SETDB1 in human tumors. J Oncol. 2022;2022:6115878. doi:10.1155/2022/6115878
  • Saito Y, Koya J, Kataoka K. Multiple mutations within individual oncogenes. Cancer Sci. 2021;112(2):483–489. doi:10.1111/cas.14699
  • Cortés-Ciriano I, Lee JJ, Xi R, et al. Comprehensive analysis of chromothripsis in 2658 human cancers using whole-genome sequencing. Nat Genet. 2020;52(3):331–341. doi:10.1038/s41588-019-0576-7
  • Liu L, He J, Sun G, et al. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clin Transl Med. 2022;12(5):e778. doi:10.1002/ctm2.778
  • Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26(3):165–176. doi:10.1016/j.tcb.2015.10.014
  • Guo J, Xu B, Han Q, et al. Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res Treat. 2018;50(2):445–460. doi:10.4143/crt.2016.572
  • Fang X, Cai Z, Wang H, et al. Loss of cardiac ferritin H facilitates cardiomyopathy via Slc7a11-mediated ferroptosis. Circ Res. 2020;127(4):486–501. doi:10.1161/circresaha.120.316509
  • Lang X, Green MD, Wang W, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9(12):1673–1685. doi:10.1158/2159-8290.Cd-19-0338
  • Qian L, Wang F, Lu SM, et al. A comprehensive prognostic and immune analysis of ferroptosis-related genes identifies SLC7A11 as a novel prognostic biomarker in lung adenocarcinoma. J Immunol Res. 2022;2022:1951620. doi:10.1155/2022/1951620
  • Lin Y, Dong Y, Liu W, Fan X, Sun Y. Pan-cancer analyses confirmed the ferroptosis-related gene SLC7A11 as a prognostic biomarker for cancer. Int J Gen Med. 2022;15:2501–2513. doi:10.2147/ijgm.S341502
  • Liu R, Liu L, Bian Y, et al. The dual regulation effects of ESR1/NEDD4L on SLC7A11 in breast cancer under ionizing radiation. Front Cell Dev Biol. 2021;9:772380. doi:10.3389/fcell.2021.772380
  • Li Y, Zeng X, Lu D, Yin M, Shan M, Gao Y. Erastin induces ferroptosis via ferroportin-mediated iron accumulation in endometriosis. Hum Reprod. 2021;36(4):951–964. doi:10.1093/humrep/deaa363
  • Ng SW, Norwitz SG, Taylor HS, Norwitz ER. Endometriosis: the role of iron overload and ferroptosis. Reprod Sci. 2020;27(7):1383–1390. doi:10.1007/s43032-020-00164-z
  • Bielfeld AP, Pour SJ, Poschmann G, Stühler K, Krüssel JS, Baston-Büst DM. A proteome approach reveals differences between fertile women and patients with repeated implantation failure on endometrial level – does hCG render the endometrium of RIF patients? Int J Mol Sci. 2019;20(2):425. doi:10.3390/ijms20020425
  • Zhang M, Zhang T, Song C, et al. Guizhi Fuling Capsule ameliorates endometrial hyperplasia through promoting p62-Keap1-NRF2-mediated ferroptosis. J Ethnopharmacol. 2021;274:114064. doi:10.1016/j.jep.2021.114064
  • Tokunaga H, Shimada M, Ishikawa M, Yaegashi N. TNM classification of gynaecological malignant tumours, eighth edition: changes between the seventh and eighth editions. Jpn J Clin Oncol. 2019;49(4):311–320. doi:10.1093/jjco/hyy206
  • Chang MT, Asthana S, Gao SP, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34(2):155–163. doi:10.1038/nbt.3391
  • Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23–38. doi:10.1038/npp.2012.112
  • Sokratous G, Polyzoidis S, Ashkan K. Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme. Hum Vaccin Immunother. 2017;13(11):2575–2582. doi:10.1080/21645515.2017.1303582
  • Braun DA, Hou Y, Bakouny Z, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26(6):909–918. doi:10.1038/s41591-020-0839-y
  • Luo L, Li L, Liu L, et al. A necroptosis-related lncRNA-based signature to predict prognosis and probe molecular characteristics of stomach adenocarcinoma. Front Genet. 2022;13:833928. doi:10.3389/fgene.2022.833928
  • Lopez de Rodas M, Nagineni V, Ravi A, et al. Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. J Immunother Cancer. 2022;10(6):e004440. doi:10.1136/jitc-2021-004440
  • Gao W, Wang X, Zhou Y, Wang X, Yu Y. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct Target Ther. 2022;7(1):196. doi:10.1038/s41392-022-01046-3
  • Ferrall L, Lin KY, Roden RBS, Hung C-F, Wu T-C. Cervical cancer immunotherapy: facts and hopes. Clin Cancer Res. 2021;27(18):4953–4973. doi:10.1158/1078-0432.Ccr-20-2833